A Randomized, Open-Label, Single-Dose, Crossover Study to Demonstrate the Bioequivalence of the Final Fixed Dose Combination (FDC) Formulation (COREG CR [carvedilol] and Lisinopril) to COREG CR and ZESTRIL [Lisinopril] Employed in the Phase III Factorial Study
Latest Information Update: 22 Aug 2023
At a glance
- Drugs Carvedilol/lisinopril (Primary) ; Carvedilol; Lisinopril
- Indications Heart failure; Hypertension
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 12 Jun 2008 Actual patients number 55 added as reported by ClinicalTrials.gov.
- 12 Jun 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Nov 2007 New trial record.